Recital 42, Regulation (EU) 2026/2348

In force

The application for the renewal of the approval of the active substance acequinocyl was submitted on 27 May 2022 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 5 May 2023 that it had assessed the admissibility of the application pursuant to Article 8 of Implementing Regulation (EU) 2020/1740, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority, which conducted a public consultation on it between 8 January and 8 March 2024, pursuant to Article 10 of Implementing Regulation (EU) 2020/1740. On 19 February 2026, the rapporteur Member State submitted the draft renewal assessment report to the Authority. The Authority estimates that it will be able to finalise its conclusion for acequinocyl by the end of December 2027, and as the Commission will need time to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 26 months, until 15 January 2029.